With high‑potency obesity therapies poised to reshape care
Market Access Pharma
July 25, 2025
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
